By Sean Moloughney, Editor01.27.23
FDA announced Jan. 26 that “the existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol” and it wants guidance from Congress on “a new regulatory pathway.”
Natural Products Association (NPA) President and CEO Daniel Fabricant, PhD, didn’t mince words, saying the agency’s action amounted to “an astonishing dereliction of duty, especially compared to the agility and professionalism the agency showed it was capable of during the pandemic.”
“After more than a decade of promises, hearings, data sharing, market proliferation, and states filling the regulatory vacuum, the FDA’s Dietary Supplement Division claims it cannot do what Congress authorized, which is to regulate dietary supplements under the law,” Fabricant said.
“But it gets scarier,” he continued.
When reading between the lines of FDA
Natural Products Association (NPA) President and CEO Daniel Fabricant, PhD, didn’t mince words, saying the agency’s action amounted to “an astonishing dereliction of duty, especially compared to the agility and professionalism the agency showed it was capable of during the pandemic.”
“After more than a decade of promises, hearings, data sharing, market proliferation, and states filling the regulatory vacuum, the FDA’s Dietary Supplement Division claims it cannot do what Congress authorized, which is to regulate dietary supplements under the law,” Fabricant said.
“But it gets scarier,” he continued.
When reading between the lines of FDA
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
